A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE DOSTARLIMAB AS SEQUENTIAL THERAPY AFTER CHEMORADIATION IN PARTICIPANTS WITH LOCALLY ADVANCED UNRESECTED HEAD AND NECK SQUAMOUS CELL CARCINOMA

Registry ID
221530
Source registry
HEALTH_CANADA
Status
Ongoing
Phase
PHASE3
Study type
INTERVENTIONAL
Sponsor
GLAXOSMITHKLINE INC
Start date
2024-02-29
Last update
2023-12-22

Conditions

Related clinical trials

View on source registry